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Treatment as prevention (TasP) not only stands for pre-
vention of HIV transmission by treating HIV-positives,
but also for prevention of morbidity and mortality in those
positives. Mathematical models have shown that it should
be possible to “eradicate” HIV at the population level, or
at least come close to it, if this approach were rigorously
applied.
But these optimistic models are based on assumptions
which are not realistic:
• That it is possible to test the whole adult popula-
tion every year;
• That every individual found to be HIV positive will
accept immediate antiretroviral treatment;
• That those accepting antiretroviral treatment will
all be therapy adherent;
• That there will be no drug stock-outs;
• That there will be no development of antiretroviral
drug resistance.
We should realize, however, that early treatment is
good for an individual’s own benefit, and that this is the
overriding reason to test as many people as possible and
offer them antiretrovirals.
Early treatment prolongs life expectancy, prevents co-
morbidities, and allows for task shifting from doctors to
nurses and community workers. Moreover it will reduce
TB incidence, which is not a trivial fact in resource poor
settings. Early treatment thus presents an enormous
opportunity to save lives, reduce HIV transmission and
tackle the dual epidemic of HIV and TB. The world must
be willing, however, to surmount the enormous hurdles
(financial, logistical) that stand in the way of realization of
this opportunity.
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